Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Aberdeen Group plc

Aberdeen Group plc boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 314,889 shares of the pharmaceutical company’s stock after purchasing an additional 26,922 shares during the period. Aberdeen Group plc owned approximately 0.12% of Vertex Pharmaceuticals worth $123,323,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Chesapeake Asset Management LLC boosted its stake in shares of Vertex Pharmaceuticals by 110.0% during the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after acquiring an additional 33 shares in the last quarter. Access Investment Management LLC acquired a new position in Vertex Pharmaceuticals in the second quarter valued at about $27,000. Legacy Investment Solutions LLC acquired a new position in Vertex Pharmaceuticals during the 2nd quarter worth about $29,000. Total Investment Management Inc. bought a new position in Vertex Pharmaceuticals in the second quarter valued at about $33,000. Finally, Financial Network Wealth Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 50.9% in the 3rd quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company’s stock worth $34,000 after purchasing an additional 29 shares during the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Trading Up 5.7%

Shares of VRTX opened at $491.47 on Friday. The stock’s 50-day moving average price is $459.98 and its two-hundred day moving average price is $427.48. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.68. The company has a market capitalization of $124.70 billion, a PE ratio of 32.06 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.90%. The firm had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.18 billion. During the same period in the prior year, the company posted $3.98 earnings per share. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and product momentum — Q4 revenue of ~$3.19B (≈+9.5% YoY) came in at or slightly above many forecasts, driven by cystic fibrosis product sales and new launches (Alyftrek, Casgevy, Journavx), supporting near-term cash flow expectations. Article Title
• Positive Sentiment: Analyst upgrade and bullish targets — Oppenheimer upgraded VRTX to “outperform” with a $540 target; several other firms recently raised targets or reiterated buys, which can drive momentum and institutional demand. Article Title
• Positive Sentiment: Pipeline diversification highlighted — Company commentary emphasized growth beyond CF (autoimmune partnerships/expansion), which reduces concentration risk and supports longer-term upside. Article Title
• Neutral Sentiment: 2026 revenue guidance roughly in-line — Management set FY2026 revenue guidance around $13.0–13.1B, largely matching Street expectations; this limits downside from guidance surprises but is not a bullish catalyst on its own. Article Title
• Neutral Sentiment: Full materials available for modeling — The slide deck and earnings call transcript are posted; analysts will parse product trends and margins to update models. Article Title
• Negative Sentiment: Small EPS miss and mixed metric comparisons — EPS was ~$5.03 vs. consensus near $5.05–$5.07; some outlets flagged revenue slightly below certain Street models, triggering near-term profit-taking. Article Title
• Negative Sentiment: Insider selling — Multiple senior executives disclosed open-market sales this week (EVPs, CAO). While common for tax/diversification, the cluster of sales can amplify short-term negative sentiment. Article Title
• Negative Sentiment: After-hours weakness — The EPS miss plus insider sales pressured shares in after-hours trading, reflecting short-term profit-taking before today’s rebound. Article Title

Insider Buying and Selling

In related news, EVP Jonathan Biller sold 1,925 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $886,327.75. Following the completion of the sale, the executive vice president directly owned 20,819 shares of the company’s stock, valued at $9,585,692.17. The trade was a 8.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Mark E. Bunnage sold 2,021 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $930,529.03. Following the transaction, the executive vice president directly owned 12,914 shares in the company, valued at approximately $5,945,993.02. This trade represents a 13.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 99,352 shares of company stock worth $45,037,314 over the last 90 days. 0.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on VRTX shares. HC Wainwright increased their target price on Vertex Pharmaceuticals from $478.00 to $518.00 and gave the stock a “buy” rating in a research note on Friday. Sanford C. Bernstein reissued an “outperform” rating and set a $577.00 target price on shares of Vertex Pharmaceuticals in a report on Friday. Royal Bank Of Canada decreased their price target on Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating on the stock in a research report on Friday. Wells Fargo & Company upped their price objective on shares of Vertex Pharmaceuticals from $460.00 to $515.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Finally, Oppenheimer raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 target price on the stock in a report on Friday. Twenty-two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $537.05.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.